Clinical trials: Neoplasm Circulating Cells
Colon Cancer
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
Colorectal cancer remains the commonest cancer among men, and third commonest among women in Saudi Arabia . Presentation with metastatic disease occurs in almost one third of patients , with 5-year survival decreasing…
- Trial name
- NCT04775862
- Testing
- investigator choice re-challenge with anti EGFR Rx
- Where
- Saudi Arabia
- Volunteers
- 60 people
- Sponsor
- National Guard Health Affairs
Bladder Cancer, Urothelial Carcinoma
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
- Trial name
- RETAIN-3 (NCT07908979)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer, Circulating Tumor Cell
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
clinical trial The goal of this clinical trial is to learn whether the treatment of advanced non-small cell lung cancer with EGFR-TKIs, when combined with bevacizumab in the presence of positive circulating tumor cells in the…
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- NCT06557096
- Testing
- Osimertinib 80 MG, Bevacizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Breast Cancer
Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with current or previous cancer may help doctors learn more about biomarkers related to cancer.
- Trial name
- NCT00898703
- Testing
- flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arizona
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different…
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06678724
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Gastric Cancer
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
To evaluate the clinical significance of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in real-time monitoring the therapeutic response during HER2-targeted therapy in histologically confirmed HER2 positive…
- Trial name
- NCT02610218
- Testing
- CTC and cfDNA analysis
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Peking University
Breast Cancer, Circulating Tumor Cell
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients…
- Trial name
- CTCNeoBC-E (NCT05360290)
- Testing
- GILUPI CellCollector®
- Where
- China
- Volunteers
- 484 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer
Circulating DNA in Surgically Treated NSCLC
The investigators will prospectively recruit 100 NSCLC patients. The cfDNA samples will be gathered before the surgery and postoperatively 4-6 weeks after surgery and at 6 and 12 months follow-up visits.
- Trial name
- NCT04037150
- Testing
- Circulating tumor DNA
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Stage II Bladder Urothelial Carcinoma
Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer
This pilot clinical trial studies the impact of radical cystectomy (surgery) on the expulsion (release) of circulating tumor cells into the blood stream in patients with bladder cancer.
- Trial name
- NCT02514408
- Testing
- Catheter Management, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Sponsor
- University of Southern California
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.
- Trial name
- NCT02623257
- Testing
- mutation detection, ARMS, ctDNA analysis
- Where
- China
- Volunteers
- 1,055 people
- Sponsor
- First People's Hospital of Hangzhou
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Gastric Cancer Stage IV
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
BACKGROUND: Gastric cancer is one of the most common cancers and is one of the most deadly cancers. Most patients have advanced disease and should receive first-line trastuzumab-associated chemotherapy when the biopsy is positive…
- Trial name
- GASTHER2 (NCT04168931)
- Testing
- Trastuzumab
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- AC Camargo Cancer Center
Lung Squamous Cell Carcinoma
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell…
- Trial name
- NCT05778253
- Testing
- WES and ctDNA detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Xiangya Hospital of Central South University
Breast Cancer
Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer
RATIONALE: Measuring blood levels of tumor cells in patients with breast cancer may help doctors predict how patients will respond to treatment.
- Trial name
- NCT00898014
- Testing
- fluorescence in situ hybridization, immunologic technique, laboratory biomarker analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Institut Curie
Circulating Tumor Cell, Oropharyngeal Cancer
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Head and neck cancers (HNSCC) are primarily squamous cell cancers represented by tumors of the upper aerodigestive tract. Locally advanced stages (stages III and IV) account for 50 to 70% of all presentations.
- Trial name
- CTCO (NCT04696744)
- Testing
- CTC detection
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Cancer, Pancreatic Adenocarcinoma
EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients
The study aims at evaluating the feasibility and safety of EUS-guided Portal Circulation sampling for isolation, enumeration and profiling od Circulating Tumor Cells (CTC) in Pancreatic Cancer patients.
- Trial name
- EUPhORIC (NCT05247164)
- Testing
- EUS-guided Portal Vein sampling
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- IRCCS San Raffaele
Lung Cancer Recurrent
Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients
From literature review, circulating tumor cell was demonstrated its possible role in disease relapse. It was rare nit could be identified in all lung cancer patients.
- Trial name
- NCT03721133
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Chang Gung Memorial Hospital
Cervical Cancer, HPV
CTCs in Cervix Cancer
This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer.
- Trial name
- NCT04064515
- Testing
- Blood Assayed for CTCs
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- NYU Langone Health
Uveitis, Lymphoma
Screening for Oculocerebral Lymphoma With the Phenotype of NK Cells in Patients With Uveitis
Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor.
- Conditions
- Uveitis, Lymphoma, NK-Cell Lymphoma
- Trial name
- DeLPHy (NCT05388838)
- Testing
- Blood sample
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon
Glioma, IDH1/IDH2 Mutation
Non Invasive Detection of IDH1/2 Mutation in Gliomas
This trial develops a non invasive diagnostic approach of IDH1 mutated gliomas combining mutation detection from free plasmatic DNA, D-2HG dosage in urine samples, and D-2HG detection by Brain Spectro MRI.
- Trial name
- IDASPE (NCT02597335)
- Testing
- Spectro-MRI, Dosage of free circulating plasmatic DNA, Dosage of D-2HG in the urine
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris